Munson Healthcare Media Appearances March 15, 2024 Q100 Northern Focus Podcast Kirsten Korth-White, President of East Region Community Hospitals, Mike Hodnett, Chief Operations Officer/Chief Nursing Officer for Grayling Hospital, and...

Hospital Stays for Children and Teens Children and teens may be hospitalized at Charlevoix Hospital, Grayling Hospital, Manistee Hospital, Mackinac Straits Health System in St. Ignace, Munson Medical Center in Traverse City, and Otsego Memorial...

Keeping Our Patients Safe We have implemented many safeguards to ensure you have a safe and secure hospital stay. Below are some of the safety steps we take and how you can be involved in your own safety. Patient...

What to Know About RSV  What Is RSV?  Respiratory syncytial virus (RSV) is a common and highly contagious respiratory virus that affects the lining of the respiratory system, including the nose, throat, lungs, and breathing...

New CDC data shows nirsevimab, a long-acting monoclonal antibody, was highly effective in protecting infants from RSV-associated hospitalizations. RSV is the leading cause of hospitalization among infants in the U.S. For details, read the CDC news...

The CDC has issued a health advisory due to low vaccination rates against influenza, COVID-19, and RSV (respiratory syncytial virus), which could lead to more severe disease and increased healthcare capacity strain in the coming weeks. Also, a...

In response to a recent shortage of Beyfortus (Nirsevimab) — a long-acting monoclonal antibody for prevention of severe RSV among infants and children — the CDC has announced the release of 77,000 additional doses for hospitals and...

Beyfortus (Nirsevimab) — a long-acting monoclonal antibody for prevention of severe respiratory syncytial virus (RSV) among infants and children — is now available for providers to order. Nirsevimab may be given in child's 1st year...

RSV Vaccine for Babies, Toddlers: The FDA approved the 1st respiratory syncytial virus (RSV) vaccine for babies and toddlers. Beyfortus (nirsevimab-alip) is approved for the prevention of RSV lower respiratory tract disease in children <24...